Sample Size Estimates for Clinical Trials of Vasospasm in Subarachnoid Hemorrhage

Abstract

Background and Purpose-Clinical trials for prevention of vasospasm after aneurysmal subarachnoid hemorrhage (SAH) seldom have improved overall outcome; one reason may be inadequate sample size. We used data from the tirilizad trials and the Columbia University subarachnoid hemorrhage outcomes project to estimate sample sizes for clinical trials for reduction of vasospasm after SAH, assuming trials must show effect on 90-day patient-centered outcome. Methods-Sample size calculations were based on different definitions of vasospasm, enrichment strategies, sensitivity of short-and long-term outcome instruments for reflecting vasospasm-related morbidity, different event rates of vasospasm, calculation of effect size of vasospasm on outcome instruments, and different treatment effect sizes. Sensitivity analysis was performed for variable event rates of vasospasm for a given treatment effect size. Sample size tables were constructed for different rates of vasospasm and outcome instruments for a given treatment effect size. Results-Vasospasm occurred in 12% to 30% of patients. Symptomatic deterioration and infarction from vasospasm exhibited the strongest relationship to mortality and morbidity after SAH. Enriching for vasospasm by selection of patients with thick SAH slightly decreased sample sizes. Assuming ␤ϭ0.80, ␣ϭ0.05 (2-tailed) and treatment effect size of 50%, total sample size exceeds 5000 patients to demonstrate efficacy on 3-month patient-centered outcome (modified Rankin Scale). Conclusions-Clinical trials targeting vasospasm and using traditional patient-centered outcome require very high sample sizes and will therefore be costly, time-consuming, and impractical. This will hinder development of new treatment strategies.

Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH)

“…25 A post hoc power analysis with 63% favorable outcome in the control group yielded 0.85 for 15% improvement and 0.49 for 10% improvement. Although there may be doubt about underpowering of the study based on a 50% unfavorable outcome and 15% improvement in outcome from Veyna's series 10 and we did consider revising the sample size based on a lower rate of unfavorable outcome and lesser degree of improvement in outcome, 11 the lack of any trends on the different clinical outcome measures and subgroup analysis supports the validity of our negative result.…”

Prospective, Randomized, Open-Label Phase II Trial on Concomitant Intraventricular Fibrinolysis and Low-Frequency Rotation After Severe Subarachnoid Hemorrhage

“…7 In addition, our study might have still been underpowered to show a beneficial effect of our experimental treatment on clinical outcome. 25 In this respect, more recent studies suggest cerebral infarction as a more robust and comprehensive outcome measure to study effectiveness of experimental treatment on DCI and function outcome. 26,27 In summary, concomitant intraventricular fibrinolysis and kinetic therapy effectively reduced subarachnoid clot volume, but not the incidence of DCI and poor functional outcome in patients experiencing severe SAH.…”

Biomarkers in Neurocritical Care

“…CT can detect clinically asymptomatic infarcts, particularly in patients with low GCS [69,70]. MRI can detect a larger proportion of asymptomatic infarcts compared to CT [71], and importantly the overall burden of infarcts is correlated with outcome [72,73].…”